K awasaki disease (KD) is the most common cause of acquired pediatric heart disease. The etiology remains unknown but involves a complex interaction between host genetics and environmental triggers that result in different clinical outcomes. 1 Acute KD is characterized by high fevers, mucocutaneous changes, and elevated markers of systemic inflammation. Coronary artery aneurysms (CAA) are the most serious sequelae and occur in 25% of untreated patients, but early treatment with intravenous immunoglobulin and aspirin reduces the risk for CAA to 5%. 2 Although current American Heart Association guidelines identify increased risk of cardiovascular sequelae in patients with CAA, especially giant CAA, they do not recommend additional anti-inflammatory therapy beyond the acute illness for these patients. 3 Cardiac imaging and autopsy evidence suggest that tissue-level inflammation in patients with CAA can persist and may contribute to subsequent morbidity. 4, 5 Adjunctive therapies to reduce vascular inflammation are in earlystage clinical trials, but the effect of such treatments on subclinical inflammation is difficult to monitor. 6 Standard clinical laboratory tests, such as high-sensitivity CRP [C-reactive protein] (hsCRP), white blood cell count, and erythrocyte sedimentation rate, normalize in all patients in the convalescent stage. Thus, while selected patients with CAA might benefit from additional therapy to prevent progressive tissue damage, there is no established laboratory test to ascertain ongoing tissue-level inflammation in pediatric and adult KD patients.
In this study, we initially focused on a small pediatric KD cohort with different clinical outcomes and applied a combination of integrated analytical methods for intensive, longitudinal molecular profiling. These integrated analyses highlighted biology linked to inflammation, tissue damage, and fibrotic processes. We observed elevated levels of inflammatory markers that persisted into the convalescent phase in those with giant CAA. This led us to study a cohort of adult KD patients with persistent giant CAA and age-and sex-matched adult healthy volunteers by MS-based shotgun proteomics. A surprising signature of inflammation, immune regulation, and cell trafficking was revealed. A comparison of the pediatric and adult KD analyses highlighted calprotectin as a specific marker of persistent inflammation in children and adults with giant CAA.
METHODS
Data will be made available for analysis, on request. Study materials will not be made available because of limited availability of samples. The study was reviewed and approved by the Human Research Protection Program of the University of California San Diego. Parental or subject informed consent and child and adolescent assent were obtained as appropriate from all participants. Methods are provided in a detailed Methods section in the Data Supplement. Analyses of the pediatric and adult biological samples were conducted in 3 studies as described in Figure 1 .
RESULTS

High-Resolution Molecular Profiling of Pediatric KD Patients
Longitudinal samples from 8 pediatric patients with KD were analyzed by both targeted analysis (whole-blood transcript profiling) and broad analytics (proteomics and glycomics analysis). A set of 598 analytes was measured for each patient sample. Unsupervised clustering revealed 2 distinct groups ( Figure 2 ). The membership of these clusters was consistent across several distance metrics (Euclidean, Manhattan, Pearson, and Spearman) and agglomeration methods (Ward, Complete, and Average). One of the clusters consisted mostly of samples taken at the acute phase of disease; the other cluster contained mostly the subacute and convalescent samples. These 2 clusters were named, and hereafter referred to, as active disease and resolved disease groups. Note that several subacute and convalescent samples from patients 1 and 2 clustered with the acute stage samples.
The clinical course of each patient, indicated by clinical manifestations and standard laboratory values over time, including CRP levels, was consistent with the cluster analysis into active and resolved disease groups for most patients (Figure 2 ). Patients 4 through 8 transitioned from an active molecular phenotype in the acute stage to the resolved phenotype in their subacute stage, as was also indicated by the normalization of their CRP levels ( Figure I in the Data Supplement). These patients became afebrile after initial treatment with no further complications. In addition, all sample time points from patient 8 exhibited the resolved phenotype, which corresponded with consistently low CRP levels and elevated platelet count at diagnosis, indicating that his acute disease was already resolving at the time of diagnosis on illness day 8. Patient 3, who was 14 months old, had CAA at the time of diagnosis on illness day 10; this CAA enlarged to a giant CAA in the subacute period, as noted on illness day 18. He was treated with intravenous immunoglobulin and infliximab at the time of diagnosis and enoxaparin during his subacute and late subacute period, with subsequent normalization of his CRP levels and remodeling of his aneurysm by illness day 47 (late subacute). Similarly, he exhibited an active disease phenotype at diagnosis, but both his late subacute and convalescent molecular profiles showed a resolved disease phenotype (Figure 2) .
Interestingly, most of the subacute and convalescent samples from patients 1 and 2, who developed persistent giant CAA, were grouped with the active dis-ease group ( Figure 2 ) and were consistent with their CRP levels, which remained elevated even though both became afebrile in their subacute stages. Although CRP levels normalized in patient 1 at the late subacute time point (illness day 37) and in patient 2 at his convalescent time point (illness day 70), convalescent samples of patient 1 continued to show an active disease phenotype and diverged from his apparently resolved clinical course. Patient 1 was lost to follow-up, whereas patient 2 experienced a myocardial infarction 1 year after his late convalescent blood sample and went on to require cardiac transplantation for ischemic cardiomyopathy.
Evaluation of the molecular analytes differentially expressed between the active and resolved clusters highlighted biological processes associated with active disease (Table) . These signatures included increased innate immune response and neutrophil-related transcripts and proteins (S100A8, S100A9, S100A12, IL [interleukin]-1RN, IL-1B, CEACAM8, and SAA2), as well as transcripts and proteins related to myofibroblast transformation (VCAN), cardiovascular tissue damage (MMP9), and cell trafficking (S100A11 and CEP290). Patients with active disease also showed an increase in tetra-antennary trisialylated and tetrasialylated N-glycan species with fucose on the outer arm, likely sialyl-Lewis X antigen structures (Table) . These glycan structural changes were predominantly observed in the high abundant protein fraction, which includes several acute phase proteins. Sialyl-Lewis X antigen has previously been associated with inflammation in particular glycoproteins involved in the acute phase response, and its presence on membrane glycoproteins on leukocytes is responsible for leukocyte interaction with E-selectin ligands on endothelial walls and the initiation of inflammation. [7] [8] [9] Additionally, analytes that showed abnormal values (evaluated as a fold change) in the convalescent samples of patients 1 and 2 relative to the convalescent samples of the remaining patients (patients 3-8; Table I in the Data Supplement) had considerable overlap with analytes differentially expressed between the active and resolved clusters (Table) . This suggested the persistence of inflammation and tissue remodeling in patients 1 and 2 even at their clinically apparent convalescent stage. These observations led us to study a cohort of young adults who had a history of KD with giant aneurysms as children, to assess the persistence of this molecular signature.
Shotgun Proteomics Analysis of Adult KD Cohort With Giant CAA
In our adult KD cohort, we focused more narrowly on MS-based shotgun proteomics. Because of the patients' risk for thrombosis, the majority were on warfarin. Therefore, in our shotgun proteomics data analysis, we adjusted for the warfarin effect to focus on disease-related rather than treatment-related effects. After applying protein filter criteria, 533 proteins were included in the data analysis. A linear mixed-effects model with an additional term indicating warfarin use and a random effect for matched pairs was used to calculate P while accounting for the matched design. A total of 88 differentially expressed proteins with BH P <0.05 were identified (Table II in the Data Supplement). These proteins were evaluated for differential expression and fold change ( Figure 3A) . Surprisingly, high levels of mediators of inflammation and suppressors of inflammation were detected in these adults who were otherwise healthy and had normal hsCRP levels. Notably, the proinflammatory molecules, S100A8 and A9 secreted by neutrophils and monocytes, and ANXA1 were abundant, while molecules involved in the downregulation of inflammation (SERPINB1 and CLC) were also higher in KD adults versus healthy controls. An additional molecular network associated with KD adults involved cell trafficking, with higher levels of CFL1, WDR1 (WD repeat protein 1), PFN1, CORO1A, ANXA6, and S100A4. Ingenuity pathway analysis was also conducted using the differentially expressed proteins (BH P<0.05) in adult KD patients when compared with matched adult controls. This analysis suggested that top networks associated with these proteins included inflammatory response, cellular migration, and organismal injury and abnormality (Table III in the Data Supplement). Clinically, 6 of the 9 adults had a remote history of myocardial infarction as a complication of their giant CAA.
We further analyzed log fold changes of proteins that were found in both the pediatric and adult KD cohorts. A total of 459 proteins were identified in the pediatric KD cohort, and 533 proteins were identified in the adult KD cohort. Of these, 200 were identified in both cohorts. For the pediatric KD cohort, fold changes were calculated by comparing convalescent samples for patients 1 and 2 (giant CAA) versus convalescent samples for the remaining patients (3) (4) (5) (6) (7) (8) . Adult KD cohort fold changes were calculated using a linear mixed-effects model with an additional term indicating warfarin use. The resulting scatterplot shows that fold change values for S100A8 and A9 were consistent in the 2 cohorts ( Figure 3B ).
Evaluation of Calprotectin (S1008/ S1009 Heterodimer) Levels and Tissue Localization
The consistent fold change of S100A8 and A9 in pediatric KD patients with CAA at the subacute and convalescent phases and the adult KD patients with giant CAA led us to focus on this biomarker in expanded cohorts of pediatric and adult KD subjects. These 2 calcium-binding proteins form a heterodimer in the plasma referred to as calprotectin, and levels were measured by ELISA in the plasma of pediatric KD patients (n=28) at 1 year post-KD, adult KD patients (n=70, including 9 subjects assessed by shotgun proteomics) with and without CAA, and healthy, age-and sex-matched adult volunteers (n=86). The Spearman correlations between S100A8 and A9 proteins measured by shotgun proteomics and calprotectin measured by ELISA in adult KD patients with giant CAAs were 0.93 and 0.98, respectively (Figure II in the Data Supplement).
In the pediatric patients, calprotectin levels at 1 year post-KD were elevated only in patients with giant CAA (giant aneurysm: median, 1150.4 ng/ mL; interquartile range, 634.5-2262.9 ng/mL versus aneurysm: median, 385.4 ng/mL; interquartile range, 329.6-459.7 ng/mL; Figure 4A ). In the 15 adult KD patients who had giant CA, calprotectin levels were significantly higher compared with healthy adult volunteers and the other adult KD groups (giant aneurysm: median, 751.7 ng/mL; interquartile range, 425.3-2110.8 ng/mL versus aneurysm: median, 428.5 ng/mL; interquartile range, 318.6-644.2 ng/mL; Figure 4B ). All 4 of the patients with a calprotectin level >3 SD above the mean for the normal controls (mean for normal controls+3 SD=2295 ng/mL) had a remote history of myocardial infarction compared with only 5 of 11 (45.5%) patients whose levels were <2295 ng/mL. We also compared serum hsCRP levels as an established marker of vascular inflammation among the adult KD patient groups. Surprisingly, there was no statistically significant difference across all groups ( Figure 4C ). There was also no significant correlation between hsCRP and calprotectin measurements in adult healthy controls and adult KD patient groups (data not shown).
Serial plasma samples were measured by ELISA in 2 subjects with giant CAA ( Figure 5 ). Calprotectin levels were high (5634 ng/mL) in a child with acute KD but fell rapidly (2335 ng/mL) after treatment with intravenous immunoglobulin, despite the persistence of giant CAA. In an adult with giant CAA who presented as a STEMI (ST-segment-elevation myocardial infarction) at 32 years of age, calprotectin levels were high 6 decades after his initial illness and rose even higher after he experienced a minor myocardial infarction with proximal extension of the thrombus in the LAD and occlusion of a septal branch.
Immunohistochemistry of stained tissues from a child 10 months after KD onset and from 2 adults decades after KD onset showed that both S100A8 and A9 were expressed in mononuclear cells infiltrating the coronary artery and myocardium ( Figure 6 ). Infiltrating cells expressed CD14 suggesting a myeloid lineage.
DISCUSSION
This study demonstrates that high-resolution, integrated analytics, when applied to longitudinal samples, can provide a comprehensive view of the clinical state of individual patients and the trajectory of their disease. The finding of persistently elevated markers of inflammation in convalescent pediatric KD patients with giant CAA led us to examine the proteomic profile in adult CAA patients who were many years out from their acute disease. The finding of elevated levels of S100A8/A9 and other proteins involved in inflammation, control of Fold change between the active and resolved disease group clusters of >1 or <1 (representing an actual fold change of 2). ABI3BP indicates Abelson interactor 1 gene family member 3-binding protein; AFM, Afamin; APR, acute phase response; AR, Androgen receptor; BCHE, cholinesterase; CDH, cadherin; CEACAM, carcinoembryonic antigen-related cell adhesion molecule; CEP, centrosomal protein; CHL, cofilin; CNDP, cytosolic non-specific dipeptidase; COL, collagen; CRP, c-reactive protein; CSF2RB, colony stimulating factor 2 receptor beta common subunit; CTS, cathepsin; CV, vardiovascular; CXCL, c-x-c motif chemokine; FCGR, fc gamma receptor; GPL, phosphatidylinositol-glycan-specific phospholipase; HB, hemoglobin subunit; HRG, histidine rich glycoprotein; IGFALS, insulin-like growth factor-binding protein complex acid labile subunit; IL, interleukin; ITIH, inter-alpha-trypsin inhibitor heavy chain; KIF, kinesin-like protein; LBP, lipopolysaccharide-binding protein; LTF, lactotransferrin; MMP, matrix metaloproteinase; OR, olfactory receptor family; PI, peptidase inhibitor; POSTN, periostin; PPP6R, protein phosphatase 6 regulatory subunit; RBP, retinol binding protein; S100, S100 calcium-binding protein; SA, serum amyloid; SERPIN, serine proteinase inhibitor; SIK, salt inducible kinase; SOD, superoxide dismutase; THB, thrombospondin; TNFRSF, tumor necrosis factor receptor superfamily member; TNX, tenascin-x; and VCAN, versican. and IL, interleukin.
*All gene symbols in the table represent HGNC gene symbol. †Structure abbreviations: all N-glycans have 2 core GlcNAcs; F at the start of the abbreviation indicates a core fucose; Ax, number (x) corresponds to the number of antenna (GlcNAc) on trimannosyl core; Gx, number (x) of linked galactose on antenna; Sx, number (x) of sialic acids linked to galactose; numbers in square brackets indicate linkage position; F(x) within the abbreviation corresponds to antennary fucose. ‡Glycans detected in high abundant protein fractions. §Glycans detected in both low and high abundant protein fractions. ‖Glycans detected in low abundant protein fractions.
inflammation, and cell trafficking in the plasma of adult KD patients with giant CAA and normal hsCRP levels decades after their acute illness was unanticipated. The convergent finding of elevated calprotectin levels in the pediatric and adult patients with giant CAA lead to the evaluation of expanded cohorts. A subset of pediatric and adult patients with giant CAA after KD had elevated calprotectin levels. Staining of tissues from autopsies and an explanted heart revealed infiltrating mononuclear cells that expressed both S100A8 and A9. Although previous autopsy and explanted heart immunohistochemistry studies have demonstrated that inflamma- Proteins were analyzed for differential expression and fold change (FC) between adults who had KD as children with giant aneurysms and age-and sex-matched healthy adult controls. The x axis is the log 2 FC, and the y axis is the −log 10 BH-adjusted P. The dashed line indicates P of 0.05. Proteins above that line are listed in Table I in the Data Supplement. Points in red represent proteins that show a ≥4-fold difference in the KD adult patients relative to the healthy adult controls. B, Scatterplot of the log 2 fold changes of proteins that were identified in both convalescent pediatric and adult giant aneurysm cohorts. Points annotated with gene symbols were found to be significant (BH-adjusted P <0.05) in the adult KD cases when compared with matched adult controls. The plot shows that fold change values for S100A8 and A9 were consistent in the pediatric and adult studies. ALDOA indicates fructose-biphosphate aldolase A; ANPEP, aminopeptidase N; ANXA, annexin; APO, apolipoprotein; ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; CA, carbonic anhydrase; CACNA2D1, voltage-dependent calcium channel subunit alpha-2/delta-1; CDH, cadherin; CFH, complement factor H; CFL, cofilin; CLC, galectin-10; CORO, coronin; DPP, dipeptidyl peptidase; ENO1, alpha-enolase; FCGR1A, Fc gamma receptor 1A; GC, vitamin D-binding protein; GDI, GDP dissociation inhibitor; GPI, glucose-6-phosphate isomerase; HB, hemoglobin; HSP, heat shock protein; HSPA, heat shock 70 kDa protein; ITIH2, inter-alpha trypsin inhibitor heavy chain H2; NCAM, neural cell adhesion molecule; PFN, profilin; PGAM, phosphoglycerate mutase; PGD, 6-phosphogluconate dehydrogenase; PGK, phosphoglycerate kinase; PRDX2, eroxiredoxin-2; S100, S100 calcium-binding protein; SERPIN, serine proteinase inhibitor; WD, tryptophan-aspartic acid; WDR1, repeat-containing protein 1; and YWHAZ, 14-3-3 protein zeta/delta. tion and inflammatory mediators can be detected in KD patients with giant CAA, there have been no biomarker studies to suggest persistent inflammation in living patients with giant CAA who have recovered from acute KD. 5, 10 Documented inflammation in 2 individuals by 18 F-fluorodeoxyglucose-Positron emission tomography scanning is the only published information that living patients may have ongoing arterial wall inflammation years to decades after KD. 11, 12 Our demonstration of persistent inflammation at the molecular level in adult patients with giant CAA suggests the need to study this population of young adults with advanced imaging and longitudinal biomarker studies to further delineate occult effects of the systemic vasculitis in childhood. Limited longitudinal data in adult patients with CAA from Japan suggest a cardiovascular event rate of >60% during the first 3 decades after KD. 13 For adult patients with giant aneurysms, elevated levels of calprotectin as a biomarker of persistent, subclinical inflammation may suggest the need to consider some form of anti-inflammatory therapy in this high-risk population. Considerable interest has been recently raised by studies of anti-inflammatory therapies in adults with atherosclerosis as a means to decrease cardiovascular event rates. 14, 15 Might the same approach also be relevant for adult KD patients with giant CAA?
In our initial analysis of the 8 pediatric KD patients over time, we observed that the acute and several of the subacute and convalescent samples for 2 of the youngest patients with giant CAA (patients 1 and 2) exhibited an active disease phenotype based on unsupervised clustering analysis using molecular analytes. Novel biomarkers that remained elevated in the post-treatment samples of pediatric patients with persistent CAA related to inflammation and tissue damage included S100 proteins, CTSD, CEACAM8, VCAN, β-actin (ACTB), and IL-1B. Increased ACTB is associated with tissue damage, including vascular damage and CEACAM8 is implicated in granulocyte-mediated regulation of inflammation. 16, 17 Previous studies also have reported changes in CTSD and VCAN in adults with abdominal aortic aneurysms, and certain isoforms of VCAN have been associated with fibroblast-to-myofibroblast transformation in abdominal aortic aneurysms. 18, 19 Myofibroblast proliferation has been documented as an important feature of the vascular pathology in KD patients. 5, 20 One possible mechanism to explain the localized persistence of innate immune activation is the recruitment of myeloid lineage cells by myofibroblasts in the arterial wall that are capable of secreting IL-17. This has been previously documented by immunohistochemistry in KD autopsy studies. 20 To explore these observations of persistent inflammation further, we analyzed an adult KD cohort by MS-based shotgun proteomics, which revealed several proteins that were differentially regulated between the adult KD patients and the adult controls. As a counterbalance to proinflammatory S100A8/9, high levels of the anti-inflammatory molecules ANXA1, CLC, and SER-PINB1 were noted. ANXA1 is expressed in neutrophils, eosinophils, and monocytes and inhibits the transendothelial migration of neutrophils and blocks their chemoattractant response. 21 ANXA1 works in concert with aspirin-triggered lipoxins to downregulate migration of neutrophils into tissues. 22 It should be noted that all of the adult KD patients with giant aneurysms, but none KD (n=28) . B, Adult KD patients (n=70) and adult healthy controls (n=86). Bar=median, box=25% to 75%, and whiskers extend to the furthest observation within 1.5× the interquartile range (IQR). P by Wilcoxon rank-sum test. C, hsCRP levels in adult KD patients (n=103) and healthy matched controls. There were no significant differences across groups.
of the controls, were taking low-dose aspirin. SERPINB1 is an intracellular protein and potent inhibitor of neutrophil elastase, 23 which is an enzyme that plays a major role in the destruction of the internal and external elastic lamina that is characteristic of KD vascular pathology. 5 CLC, also known as galectin 10, is secreted by regulatory T cells and a subset of CD16+ eosinophils and mediates suppression of proinflammatory T cells. 24, 25 Of interest, eosinophils are prominent in the aneurysm wall of the coronary artery from autopsies of adult KD patients. 26 Another molecular signature of the adult KD patients was elevated levels of proteins involved in cell trafficking and actin binding, including CFL1, WDR1, PFN1, CORO1A, ANXA6, and S100A4. [27] [28] [29] [30] Differentially expressed proteins in the adult KD cohort (adult KD patients versus matched adult controls) were compared with those in the pediatric KD patients by evaluating convalescent samples from children with persistent giant CAA (patients 1 and 2) versus convalescent samples from children with disease resolution (patients 3-8; Figure 3B ). This analysis showed that S100A8 and A9 were consistently elevated in both cohorts. These results prompted us to focus on the S100A8/A9 heterodimer, calprotectin, in expanded cohorts of patients. In pediatric KD patients 1 year after disease onset, an elevated level of calprotectin was observed only in patients with giant CAAs. This was also true for the adult KD cohort, and elevated levels occurred despite administration of statins in this cohort. Calprotectin levels did not correlate with hsCRP measurements, which were in the normal range in most patients. This finding mirrors the experience in patients with systemic onset juvenile idiopathic arthritis, another IL-1β-driven disease, in whom hsCRP can be normal in the face of smoldering inflammation and elevated levels of calprotectin. 31, 32 The calcium-binding proteins, S100A8, A9, and A12, referred have long been recognized as markers of inflammation during the acute phase of KD. [33] [34] [35] [36] [37] Abe et al showed that peripheral blood monocytes had increased transcript levels for the calgranulins and that during the subacute phase 4 of 6 patients who developed CAA had persistence of elevated levels of calprotectin. These proteins are released by monocytes and granulocytes at sites of acute inflammation in a variety of conditions including acute coronary syndrome, Takayasu aortitis, uveitis, inflammatory bowel syndrome, and autoinflammatory syndromes, and their plasma levels reflect disease activity.
38-41 S100A8 and A9 are abundant in neutrophils where they account for 30% of the cytosolic proteins. 42 These cytoplasmic proteins are a major component of neutrophil extracellular traps where they play an active role in protection against bacterial and fungal pathogens. The glycolytic enzyme, enolase 1, which was upregulated in adults with giant CAA, is also a component of neutrophil extracellular traps. 43 A pathogenic role for calprotectin in vasculitis includes activation of endothelial cells with expression of adhesion molecules and chemokines that enhance transendothelial cell migration of neutrophils. 38 In addition, these molecules serve as damageassociated molecular patterns and can signal through TLR4 (Toll-like receptor 4) and the RAGE (receptor for advanced glycation end products) to activate innate immune signaling through NFκB. 44, 45 Thus, these molecules may serve as a both markers and mediators of inflammation in KD.
Could there be other drivers of elevated plasma calprotectin in our pediatric and adult KD patients with giant CAA? None of our pediatric or young adult patients had comorbidities known to be associated with elevated calprotectin levels including autoimmune and autoinflammatory diseases, atherosclerotic heart disease, diabetes mellitus, or morbid obesity. 46, 47 Although low-dose aspirin has been associated with gut inflammation and increased fecal calprotectin, elevation of plasma calprotectin levels has not been attributed to this therapy in humans.
In addition, our patients were taking standard and not enteric-coated aspirin, which is associated with greater small bowel mucosal injury.
Although hsCRP has emerged as a useful biomarker of inflammation in adults with atherosclerotic coronary artery disease, it has proved to be an insensitive biomarker in pediatric diseases characterized by activation of the innate immune system. 48 Calprotectin was compared with serum amyloid A, erythrocyte sedimentation rate, and hsCRP as biomarkers to monitor response to therapy in pediatric patients with cryopyrin-associated periodic syndromes-an IL-1 mediated spectrum of diseases. Calprotectin emerged as the most sensitive biomarker of phagocyte activation in these patients. KD patients also have activation of the IL-1 pathway as a major signature of their acute disease. 49 In the present study, pediatric patients had normalization of the CRP levels despite persistence of a molecular signature of inflammation, and we found no difference between hsCRP levels in adult KD subjects regardless of their coronary artery status compared with healthy adult controls.
Because of their role as damage-associated molecular patterns that activate the innate immune system, S100A8 and A9 may also be therapeutic targets. 50 The quinoline-3-carboxamides are anti-inflammatory agents with no immunosuppressive action that are in clinical trials for treatment of autoimmune diseases such as multiple sclerosis. 51 Recent data suggest that these Q compounds bind directly to homodimeric S100A9, but only weakly to the S100A8/9 heterodimer, and block its binding to the proinflammatory receptors TLR4 and RAGE. 50 Thus, the calgranulins may serve as therapeutic targets for control of inflammation.
Although our initial study represents the first multiparametric (proteins, transcripts, and N-glycans) profiling of KD patients, we recognize several limitations. Our multi-omics approach to a cohort of pediatric KD patients and the follow-on shotgun proteomics study of adult KD patients with giant aneurysms included a small number of subjects. No imaging studies such as 18 F-fluorodeoxyglucosePositron emission tomography were available for the patients with persistent inflammation to localize the tissue source. The limited availability of autopsy samples and the lack of plasma samples linked to these tissues prevented a direct correlation between tissue level expression and plasma levels of calprotectin. The mechanism underlying persistent tissue-level activation of the innate immune system suggested by our data remains speculative. , (B, F, J, and M) anti-S100A8, (C, G, K, and N) anti-S100A9, (I) anti-CD14, and (D, H, L, and O) rabbit IgG control. The square region in A is magnified in B-D; square in E is magnified in F-H; squares in F-H are magnified in J, K, and L, respectively. Mononuclear cells in coronary artery and myocardium were strongly positive for S100A8 and A9 in post-KD cases but not in the control. CD14 staining was positive in mononuclear cells in a pattern similar to the positive staining for S100A8 and A9. Lu indicates lumen.
CONCLUSIONS
Exploratory studies using a multi-omics approach identified persistence of inflammation in convalescent pediatric patients with giant CAA, which was confirmed in a study of young adults with giant CAA. Calprotectin emerged as a consistent marker of inflammation in these 2 cohorts, which was validated in a larger study of pediatric and adult KD patients. This study raises concern that smoldering inflammation is present in a subset of KD patients decades after resolution of the acute disease. Whether the elevated levels of calprotectin are associated with long-term clinical consequences should be addressed by longitudinal studies of patients with giant CAA. 
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